Law Firm Reminds Nektar Therapeutics Investors of Lead Plaintiff Deadline in Securities Class Action
A law firm has issued a reminder for investors in Nektar Therapeutics who purchased securities during a specified period to file a lead plaintiff motion by May 5, 2026. The class action relates to a clinical trial failure announced in December 2025 that led to a stock price decline. The announcement detailed issues with patient eligibility in the trial.
benzinga.comA law firm announced a reminder for investors in Nektar Therapeutics who may have incurred losses on securities purchased between February 26, 2025, and December 15, 2025. The firm stated that the deadline to file a motion to serve as lead plaintiff in the class action is May 5, 2026.
December 16, 2025, Nektar Therapeutics reported topline results from the 36-week induction treatment period of its Phase 2b REZOLVE-AA trial for rezpegaldesleukin, a treatment for alopecia areata. The company stated that the trial did not achieve statistical significance and attributed this to the inclusion of four patients who were not eligible to participate.
Following the announcement, Nektar Therapeutics' stock price decreased by $4.14, or 7.8 percent.
Background on the Class Action The class action was filed on behalf of investors who acquired Nektar Therapeutics securities during the specified class period. The law firm, Glancy Prongay Wolke & Rotter LLP, indicated that the lawsuit pertains to potential securities fraud related to the trial disclosures.
Investors affected during the class period can seek further information about participating in the action.
